Cancer and thrombosis: from molecular mechanisms to clinical presentations

被引：158

作者：

Buller, H. R. ^{[1
]}

Van Doormaal, F. F. ^{[1
]}

Van Sluis, G. L. ^{[1
]}

Kamphuisen, P. W. ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2007年 / 5卷

关键词：

cancer; (lowmolecular weight) heparins; hemostasis; venous thromboembolism;

D O I：

10.1111/j.1538-7836.2007.02497.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although the bidirectional association between cancer and venous thromboembolism (VTE) has been known for almost two centuries, recent advances in our understanding of the clinical, laboratory, and epidemiologic aspects of this association have created a renewed interest in this topic. This review consists of two parts. The first part discusses the occurrence, determinants and significance of VTE in those with cancer, as well as the risk of developing and the possible need to detect cancer in those presenting with VTE. The second part reviews the role of hemostatic constituents (coagulation and fibrinolytic proteins and platelets) in promoting growth and progression of cancer, as well as the effects and possible mechanisms of the low molecular weight heparins (LMWH) in this process.

引用

页码：246 / 254

页数：9

共 108 条

[1] Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor [J].

Abe, K ;

Shoji, M ;

Chen, J ;

Bierhaus, A ;

Danave, I ;

Micko, C ;

Casper, K ;

Dillehay, DL ;

Nawroth, PP ;

Rickles, FR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8663-8668

[2] A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer [J].

Altinbas, M ;

Coskun, HS ;

Er, O ;

Ozkan, M ;

Eser, B ;

Unal, A ;

Cetin, M ;

Soyuer, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1266-1271

[3]

[Anonymous], 1865, CLINIQUE MED HOT DIE

[4] The incidence of occult cancer in patients with deep venous thrombosis: A prospective study [J].

Bastounis, EA ;

Karayiannakis, AJ ;

Makri, GG ;

Alexiou, D ;

Papalambros, EL .

JOURNAL OF INTERNAL MEDICINE, 1996, 239 (02) :153-156

[5] Signaling of the tissue factor coagulation pathway in angiogenesis and cancer [J].

Belting, M ;

Ahamed, J ;

Ruf, W .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (08) :1545-1550

[6] Heparanase expression in human leukemias is restricted to acute myeloid leukemias [J].

Bitan, M ;

Polliack, A ;

Zecchina, G ;

Nagler, A ;

Friedmann, Y ;

Nadav, L ;

Deutsch, V ;

Pecker, I ;

Eldor, A ;

Vlodavsky, I ;

Katz, BZ .

EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :34-41

[7] Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J].

Blom, JW ;

Doggen, CJM ;

Osanto, S ;

Rosendaal, FR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :715-722

[8] A functional role for hemostasis in early cancer development,. [J].

Boccaccio, C ;

Comoglio, PM .

CANCER RESEARCH, 2005, 65 (19) :8579-8582

[9] The MET oncogene drives a genetic programme linking cancer to haemostasis [J].

Boccaccio, C ;

Sabatino, G ;

Medico, E ;

Girolami, F ;

Follenzi, A ;

Reato, G ;

Sottile, A ;

Naldini, L ;

Comoglio, PM .

NATURE, 2005, 434 (7031) :396-400

[10] Axis of evil: molecular mechanisms of cancer metastasis [J].

Bogenrieder, T ;

Herlyn, M .

ONCOGENE, 2003, 22 (42) :6524-6536

← 1 2 3 4 5 6 7 8 9 10 →